JPMorgan Chase has turned a long run of strong returns on the stock into a fresh valuation debate, as investors ask whether ...
According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in ...
1d
JPMorgan makes bullish call in fixed income space, suggests it's a once in a generation opportunity
J.P. Morgan Asset Management is making a bullish call on an underinvested market group: high-quality fixed income. Priya ...
Jacob Manoukian, JPMorgan Private Bank U.S. head of investment strategy, joins 'Squawk Box' to discuss the latest market ...
JPMorgan’s ambitions come as Europe’s asset management industry is forecast to grow 5.6 per cent a year to reach almost $50tn by 2030, according to a PwC report.
Biogen (BIIB) shares rose 2.1% in Monday’s premarket trading after JPMorgan upgraded the stock to overweight from neutral, citing an increasingly attractive pipeline of catalysts expected in 2027. The ...
Jamie Dimon has spent much of this year warning that the bond market is a problem waiting to happen. On April 28, at a ...
J.P. Morgan Asset Management aims to double its European assets under management to $2 trillion within five years, betting on growing de ...
Biogen will release data from clinical trials for a few of its investigational treatments over the next few months, which should boost its shares, per JPMorgan.
Stock Q2 highlights: deposit/loan growth, wealth inflows, and IB gains. Read here for a detailed investment analysis.
Wells Fargo pays the higher dividend yield right now, but retirees living off that check need to ask what happened the last ...
JPMorgan Chase issued a report this week seeking to determine the return on $214 million in philanthropic investments it made over the past decade into developing underserved Chicago communities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results